DK1962895T3 - TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST - Google Patents

TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST

Info

Publication number
DK1962895T3
DK1962895T3 DK06848586.1T DK06848586T DK1962895T3 DK 1962895 T3 DK1962895 T3 DK 1962895T3 DK 06848586 T DK06848586 T DK 06848586T DK 1962895 T3 DK1962895 T3 DK 1962895T3
Authority
DK
Denmark
Prior art keywords
tumor growth
therapeutic use
vegf inhibitor
dll4 antagonist
dll4
Prior art date
Application number
DK06848586.1T
Other languages
English (en)
Inventor
Irene Noguera
Gavin Thurston
Nicholas Gale
Eric Smith
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38163537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1962895(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK1962895T3 publication Critical patent/DK1962895T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06848586.1T 2005-12-16 2006-12-15 TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST DK1962895T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75117305P 2005-12-16 2005-12-16
US77127606P 2006-02-08 2006-02-08
US78845606P 2006-03-31 2006-03-31
US83054306P 2006-07-12 2006-07-12
PCT/US2006/047848 WO2007070671A2 (en) 2005-12-16 2006-12-15 Therapeutic methods for inhibiting tumor growth with dll4 antagonists

Publications (1)

Publication Number Publication Date
DK1962895T3 true DK1962895T3 (da) 2013-03-04

Family

ID=38163537

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06848586.1T DK1962895T3 (da) 2005-12-16 2006-12-15 TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST

Country Status (12)

Country Link
US (1) US20080107648A1 (da)
EP (1) EP1962895B2 (da)
JP (1) JP5489465B2 (da)
AU (1) AU2006326417B2 (da)
CA (1) CA2630839C (da)
DK (1) DK1962895T3 (da)
ES (1) ES2400666T5 (da)
IL (1) IL191810A (da)
NZ (1) NZ568739A (da)
PL (1) PL1962895T3 (da)
PT (1) PT1962895E (da)
WO (1) WO2007070671A2 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
EP2032604A2 (en) * 2006-06-06 2009-03-11 Genentech, Inc. Anti-dll4 antibodies and methods using same
JP2009539870A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
AR063493A1 (es) 2006-10-19 2009-01-28 Genentech Inc Nuevos anticuerpos anti notch 3 y su uso para la deteccion y el diagnostico de enfermedades
EP2087006B1 (en) * 2006-10-19 2016-06-08 Genentech, Inc. Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008076960A2 (en) 2006-12-18 2008-06-26 Genentech, Inc. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP2120996A2 (en) * 2006-12-20 2009-11-25 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN102056945A (zh) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 针对Notch途径的单可变结构域
ES2535614T3 (es) 2008-07-08 2015-05-13 Oncomed Pharmaceuticals, Inc. Agentes de unión a Notch y antagonistas y métodos de uso de los mismos
US7544476B1 (en) * 2008-07-11 2009-06-09 Aveo Pharmaceuticals, Inc. Identifying cancers sensitive to treatment with inhibitors of notch signaling
US8192738B2 (en) * 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
AR073717A1 (es) * 2008-10-01 2010-11-24 Genentech Inc Anticuerpos anti-notch2 de murino y humano, y metodos de uso
WO2010054010A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
EP2424567B1 (en) * 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
PE20121647A1 (es) 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
US20110195494A1 (en) * 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
JP5965318B2 (ja) * 2009-10-16 2016-08-03 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストおよび降圧剤の治療的併用およびそれらによる治療の方法
EP2506875A4 (en) * 2009-12-01 2013-11-27 Oncomed Pharm Inc METHOD FOR THE TREATMENT OF TUMORS WITH K-RAS MUTATIONS
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP2523682B1 (en) 2010-01-13 2015-12-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
RU2605928C2 (ru) 2010-03-02 2016-12-27 Эббви Инк. Терапевтические dll4-связывающие белки
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
HRP20230078T1 (hr) 2011-09-23 2023-05-12 Mereo Biopharma 5, Inc. Sredstva za vezivanje vegf/dll4 i njihova uporaba
MX2015003895A (es) 2012-09-28 2015-07-17 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2/dll4 y agentes anti-vegf-r.
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
EP3743091A4 (en) 2018-01-26 2021-12-15 The Regents of the University of California METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANGIOGENIC DISORDERS USING ANTI-VEGF AGENTS
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
WO2023063842A1 (ru) * 2021-10-12 2023-04-20 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
DE69829891T2 (de) † 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
EP1004669B1 (en) * 1997-05-14 2007-04-18 Asahi Kasei Kabushiki Kaisha Novel differentiation inhibitor
NZ514918A (en) † 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ATE293164T1 (de) † 1999-06-08 2005-04-15 Regeneron Pharma Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
EP1448599A2 (en) * 2001-11-14 2004-08-25 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
JP2005511754A (ja) * 2001-12-07 2005-04-28 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 乳癌幹細胞の予測的同定および特徴づけ
WO2004024764A1 (en) 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
CA2621226A1 (en) 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
JP2009539870A (ja) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
EP2032604A2 (en) † 2006-06-06 2009-03-11 Genentech, Inc. Anti-dll4 antibodies and methods using same

Also Published As

Publication number Publication date
PT1962895E (pt) 2013-03-28
EP1962895B1 (en) 2013-02-13
JP2009519944A (ja) 2009-05-21
IL191810A0 (en) 2009-02-11
EP1962895B2 (en) 2016-01-20
NZ568739A (en) 2010-09-30
AU2006326417A1 (en) 2007-06-21
CA2630839A1 (en) 2007-06-21
WO2007070671A2 (en) 2007-06-21
ES2400666T5 (es) 2016-03-10
JP5489465B2 (ja) 2014-05-14
IL191810A (en) 2017-11-30
WO2007070671A3 (en) 2008-01-10
PL1962895T3 (pl) 2013-06-28
CA2630839C (en) 2017-01-17
EP1962895A2 (en) 2008-09-03
US20080107648A1 (en) 2008-05-08
ES2400666T3 (es) 2013-04-11
AU2006326417B2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
DK1962895T3 (da) TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
LTC1761540I2 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
DK1913157T3 (da) EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling
DK1802872T3 (da) Rörledning
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
CY2013042I2 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
DK1815247T3 (da) Terapeutisk anvendelse af farnesyltransferaseinhibitorer og fremgangsmåder til overvågning af deres effektivitet
DK1753748T3 (da) Prolinderivater og deres anvendelse som dipeptidyl-peptidase-IV-inhibitorer
DK2099796T3 (da) Aza-indolyl-forbindelser og fremgangsmåder for anvendelse
DK1771446T3 (da) Azaindolinhibitorer af MTP og APOB
CY2014013I2 (el) Αναστολεις διπεπτιδυλ πεπτιδασης
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK2073811T3 (da) Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DK2041129T3 (da) Inhibitorer af human proteintyrosinphosphatase og deres farmaceutiske anvendelse
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DK1928457T3 (da) Quinoliner og deres terapeutiske anvendelse
DK2379096T3 (da) TFPI-inhibitorer og fremgangsmåder til anvendelse
DE602005019971D1 (de) Inhibitoren von cysteinprotease
DK2463283T3 (da) Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme
DK1720866T3 (da) Fremgangsmåde
DK2015754T3 (da) Anvendelse af dpp-iv-inhibitorer
DK1723135T3 (da) Kendte hydroxy-6-heteroarylphenanthridiner og deres anvendelse som pde4-inhibitorer
DK1937276T3 (da) Forbedret testosterongel og fremgangsmåde til anvendelse deraf
DK2059246T3 (da) Terapeutiske sammensætninger omfattende en specifik endothelin-receptorantagonist og en PDE5-inhibitor